CLINICAL TRIALS PROFILE FOR GLYBURIDE AND METFORMIN HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for GLYBURIDE AND METFORMIN HYDROCHLORIDE
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00035542 ↗ | A Research Study to Determine the Safety and Efficacy of Glucovance Compared to Metformin and Glyburide in Children and Adolescents With Type 2 Diabetes. | Completed | Bristol-Myers Squibb | Phase 3 | 2001-12-01 | The purpose of this clinical research study is to see if Glucovance, a medication currently approved for use in adults with type 2 diabetes, can control type 2 diabetes safely and effectively in children 9 to 16 years of age. |
NCT00035568 ↗ | A Research Study to Assess the Mechanism By Which Glucovance, Metformin, and Glyburide Work To Control Glucose Levels In Patients With Type 2 Diabetes | Completed | Bristol-Myers Squibb | Phase 4 | 2002-02-01 | The purpose of this clinical research study is to support earlier observations that Glucovance controls glucose levels after a mean, and improves overall glucose control better than metformin or glyburide therapy alone in adults with type 2 diabetes. |
NCT00194896 ↗ | Preferred Treatment of Type 1.5 Diabetes | Completed | GlaxoSmithKline | N/A | 2000-02-01 | The purpose of this research was to test whether one treatment was superior over another in the management of type 1.5 diabetes. Specifically we tested recently diagnosed antibody positive type 2 diabetic patients to determine whether treatment with rosiglitazone results in greater preservation of beta cell function compared to treatment with glyburide. |
NCT00194896 ↗ | Preferred Treatment of Type 1.5 Diabetes | Completed | Seattle Institute for Biomedical and Clinical Research | N/A | 2000-02-01 | The purpose of this research was to test whether one treatment was superior over another in the management of type 1.5 diabetes. Specifically we tested recently diagnosed antibody positive type 2 diabetic patients to determine whether treatment with rosiglitazone results in greater preservation of beta cell function compared to treatment with glyburide. |
NCT00194896 ↗ | Preferred Treatment of Type 1.5 Diabetes | Completed | University of Washington | N/A | 2000-02-01 | The purpose of this research was to test whether one treatment was superior over another in the management of type 1.5 diabetes. Specifically we tested recently diagnosed antibody positive type 2 diabetic patients to determine whether treatment with rosiglitazone results in greater preservation of beta cell function compared to treatment with glyburide. |
NCT00232583 ↗ | Preservation of Beta-cell Function in Type 2 Diabetes Mellitus | Completed | University of Texas Southwestern Medical Center | N/A | 2003-11-01 | The study evaluates the rate beta-cell function decline in newly diagnosed type 2 diabetic patients on two different treatment regimens: insulin and metformin versus glyburide, metformin and pioglitazone. |
NCT00279045 ↗ | Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/Glibenclamide | Completed | GlaxoSmithKline | Phase 3 | 2000-01-03 | The study will compare and evaluate the effects of long-term treatment of monotherapy with rosiglitazone, metformin and glyburide/glibenclamide on the improvement and maintenance of glycemic control in patients with recently diagnosed type 2 diabetes mellitus. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for GLYBURIDE AND METFORMIN HYDROCHLORIDE
Condition Name
Condition MeSH
Clinical Trial Locations for GLYBURIDE AND METFORMIN HYDROCHLORIDE
Trials by Country
Clinical Trial Progress for GLYBURIDE AND METFORMIN HYDROCHLORIDE
Clinical Trial Phase
Clinical Trial Sponsors for GLYBURIDE AND METFORMIN HYDROCHLORIDE
Sponsor Name